TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03263273
Drug: 1% Topical Minocycline Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Study: NCT03263273
Drug: 3% Topical Minocycline Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Study: NCT00344019
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pre-PCI for ACS
Study: NCT01648140
Drug: GSK2336805 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tablet, round, 10-mm diameter, white to off-white, no markings
Study: NCT00880906
Drug: Steroid and Proton Pump Inhibitor Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377623
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
Study: NCT02725268
Drug: MLN1117
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1117 capsules.
Study: NCT00668772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Study: NCT04252131
Drug: cassia seed tablet
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional Chinese herbs
Study: NCT03351517
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
Study: NCT04508426
Drug: [14C]AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of \[14C\]AR882
Study: NCT03437746
Drug: injection of methylprednisolone at anesthetic induction
Normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
Study: NCT00869037
Drug: CFNB + Posterior Capsular Injection
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
Study: NCT00744640
Drug: gemcitabine, oxaliplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
Study: NCT03696004
Drug: FEC-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
Study: NCT01770886
Drug: UE2343
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01770886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT02927184
Drug: VK2809
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02927184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03674541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
Study: NCT03169114
Drug: Amikacin Injection
Normalized name: amikacin Injection
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
Study: NCT02795650
Drug: Personalised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
Study: NCT02795650
Drug: Treatment chosen per investigator´s judge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators are allowed to chose what they consider the best standard treatment option for their patients.
Study: NCT00002995
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02562716
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04314986
Drug: Cohort 1: AR882 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT04314986
Drug: Cohort 2: AR882 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 or matching placebo administered once daily for 10 days.
Study: NCT04314986
Drug: Cohort 3: AR882 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT04314986
Drug: Cohort 4: AR882 or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT04365400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00480766
Drug: MK0217/Duration of Treatment : 12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03122652
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once a day
Study: NCT03030417
Drug: LMP744
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
Study: NCT01335932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications.
Study: NCT01909336
Drug: 0.3% Saline in 3.3% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
Study: NCT01909336
Drug: 0.45% Saline in 5% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic Solutions: 0.45% Saline in 5% dextrose
Study: NCT01909336
Drug: 0.9% Saline in 5% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic Solutions 0.9% Saline in 5% dextrose
Study: NCT04189107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
Study: NCT03108300
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
Study: NCT01853852
Drug: GR181413A/AT1001 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for reconstitution
Study: NCT01853852
Drug: GR181413A/AT1001 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size 2, hard gelatin capsule, white opaque / blue opaque
Study: NCT01853852
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution matched
Study: NCT00002819
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00533351
Drug: AGN201781
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN201781 50 mg capsules three-times daily for 2 weeks
Study: NCT00533351
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 50 mg capsules three-times daily for 2 weeks
Study: NCT04509557
Drug: [177Lu]Ludotadipep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
Study: NCT03758950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily inhaled placebo for 48 weeks
Study: NCT00597519
Drug: Fludarabine, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.
Study: NCT00628342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily
Study: NCT02955498
Drug: Sevikar tab. 10/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
Study: NCT02955498
Drug: Lodivikar tab. 5/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
Study: NCT01301469
Drug: 6% HES 130/0.4 in a saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
Study: NCT04286529
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be created to mimic the appearance of the study drug
Study: NCT00587678
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg each night
Study: NCT00587678
Drug: Simvastatin/Ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/10mg each night
Study: NCT01444885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
Study: NCT00821496
Drug: ethinyl estradiol, norethindrone, VI-0521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive
Study: NCT00104650
Drug: IV Bisphosphonate q 4 weeks
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
Study: NCT00982826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arms information for a detailed description.
Study: NCT01643382
Drug: Insulin, Asp(B28)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
Study: NCT03472326
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03472326
Drug: ARV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
Study: NCT03472326
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03472326
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT00990743
Drug: SYL040012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
Study: NCT00683735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg 1-0-0-0
Study: NCT00683735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg 1-0-0-0
Study: NCT00414206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00307307
Drug: Niacin/simvastatin compared to simvastatin alone at 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03649165
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Study: NCT03649165
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Study: NCT00369577
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo, single dose
Study: NCT03649165
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single 500mg dose of acetaminophen at the same time.
Study: NCT02739035
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 weeks per mouth of celecoxib (200 mg daily)
Study: NCT03394027
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
Study: NCT00940992
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to face for 12 weeks
Study: NCT01126307
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tid
Study: NCT01985061
Drug: BX4-Suspended
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspended
Study: NCT02083991
Drug: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03948334
Drug: ZPL389 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg of ZPL389; once daily
Study: NCT03948334
Drug: ZPL389 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg of ZPL389; once daily
Study: NCT03948334
Drug: TCS and/or TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
Study: NCT00298974
Drug: hydrocodone / acetaminophen extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets twice daily
Study: NCT00298974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets twice daily
Study: NCT01547741
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01547741
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01884896
Drug: 'TOPROL-XL®' ER Tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 \* 200 mg tablet per day
Study: NCT04007263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via 30 minute infusion once daily for 5 days
Study: NCT04007263
Drug: NP10679
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days
Study: NCT02292719
Drug: OBV/PTV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04171050
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia injections
Study: NCT02220829
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of alpha-blocker Rapaflo only at onset of symptoms.
Study: NCT02531724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride
Study: NCT03663101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
Study: NCT00756418
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 100 to 200 mg BID 4-weeks.
Study: NCT03663101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
Study: NCT04346888
Drug: HBM9161 Injection (680mg and 340 mg)
Normalized name: INFLAMMATION AND INFECTION DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 Injection (680mg and 340mg)
Study: NCT04346888
Drug: HBM9161 Injection (340 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 Injection (340 mg)
Study: NCT02478099
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody
Study: NCT00837616
Drug: 17 B estradiol orally
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
Study: NCT00837616
Drug: 17 B estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
Study: NCT03308708
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
Study: NCT02743013
Drug: CHF 5993 100/6/12,5 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02743013
Drug: CHF 5993 100/6/12,5 DPI Test 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02743013
Drug: CHF 5993 100/6/12,5 DPI Test 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02743013
Drug: CHF 5993 100/6/12,5 pMDI replicate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04184297
Drug: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT03967054
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in the same size, color and shape at the ivermectin tablet
Study: NCT00385801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351180
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
Study: NCT02351180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will serve as a control treatment
Study: NCT01171313
Drug: Placebo for Sinemet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
Study: NCT00208767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched placebo pill will be given orally daily.
Study: NCT02163915
Drug: TAK-137 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-137 placebo-matching tablets